Novel epoxysuccinyl peptides Selective inhibitors of cathepsin B, in vitro
Mitsuo Murata(Taisho Pharmaceutical (Japan)), Satsuki Miyashita(Taisho Pharmaceutical (Japan)), Chihiro Yokoo(Taisho Pharmaceutical (Japan)), Musaharu Tamai(Taisho Pharmaceutical (Japan)), Kazunori Hanada(Taisho Pharmaceutical (Japan)), KATSUO HATAYAMA(Taisho Pharmaceutical (Japan)), Takae Towatari(Tokushima University), Takeshi Nikawa(Tokushima University), Nobuhiko Katunuma(Tokushima University)
Cited by 274
Abstract
A series of new epoxysuccinyl peptides were designed and synthesized to develop a specific inhibitor of cathepsin B. Of these compounds, N ‐(L‐3‐ trans ‐ethoxycarbonyloxirane‐2‐carbonyl)‐L‐isoleucyl‐L‐proline (compound CA‐030) and N ‐(L‐3‐ trans ‐propylcarbamoyloxirane‐2‐carbonyl)‐L‐isoleucyl‐L‐proline (compound CA‐074) were the most potent and specific inhibitors of cathepsin B in vitro. The carboxyl group of proline and the ethyl ester group or n ‐propylamide group in the oxirane ring were necessary, the ethyl ester group or the n ‐propylamide group being particularly effective for distinguishing cathepsin B from other cysteine proteinases such as cathepsins L and H, and calpains.
Related Papers
No related papers found
Powered by citation graph analysis